Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 4%

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP)’s share price shot up 4% on Monday . The company traded as high as $7.31 and last traded at $7.31. 469,948 shares were traded during trading, a decline of 73% from the average session volume of 1,722,006 shares. The stock had previously closed at $7.03.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AUPH. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a report on Monday. HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Trading Up 3.4 %

The stock has a market cap of $1.04 billion, a PE ratio of -16.98 and a beta of 1.44. The company has a quick ratio of 4.82, a current ratio of 5.33 and a debt-to-equity ratio of 0.18. The firm has a 50-day simple moving average of $6.06 and a 200-day simple moving average of $5.55.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.01. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.84%. The business had revenue of $57.10 million for the quarter, compared to analyst estimates of $54.25 million. During the same quarter in the prior year, the firm posted ($0.08) EPS. Aurinia Pharmaceuticals’s revenue was up 37.6% on a year-over-year basis. Equities analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.13 earnings per share for the current year.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, insider Scott Michael Habig sold 18,249 shares of the company’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total value of $96,902.19. Following the transaction, the insider now directly owns 456,338 shares in the company, valued at approximately $2,423,154.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC grew its position in Aurinia Pharmaceuticals by 57.7% in the fourth quarter. Armistice Capital LLC now owns 9,536,000 shares of the biotechnology company’s stock worth $85,729,000 after acquiring an additional 3,488,000 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Aurinia Pharmaceuticals by 39.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,048,456 shares of the biotechnology company’s stock valued at $18,416,000 after purchasing an additional 576,120 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Aurinia Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company’s stock valued at $7,673,000 after buying an additional 21,119 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Aurinia Pharmaceuticals by 18.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 488,721 shares of the biotechnology company’s stock worth $2,791,000 after buying an additional 77,510 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its stake in Aurinia Pharmaceuticals by 196.1% in the first quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock worth $1,750,000 after buying an additional 231,260 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.